PGE₂-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells

REFERENCES

• Almand, B., Clark, J.I., Nikitina, E., van Beynen, J., English, N.R., Knight, S.C., Carbone, D.P., and Gabrilovich, D.I. (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166:678–689.
   PubMed Web of Science ®Google Scholar
• Bankhurst, A.D. (1982). The modulation of human natural killer cell activity by prostaglandins. J. Clin. Lab. Immunol. 7:85–91.
   PubMedGoogle Scholar
• Baratelli, F., Lin, Y., Zhu, L., Yang, S.C., Heuze-Vourc’h, N., Zeng, G., Reckamp, K., Dohadwala, M., Sharma, S., Dubinett, S.M. (2005). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol. 175:1483–1490.
   PubMed Web of Science ®Google Scholar
• Basu, G.D., Tinder, T.L., Bradley, J.M., Tu, T., Hattrup, C.L., Pockaj, B.A., and Mukherjee, P. (2006). Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: Role of IDO. J. Immunol. 177:2391–2402.
   PubMed Web of Science ®Google Scholar
• Bingisser, R.M., Tilbrook, P.A., Holt, P.G., Kees, U.R. (1998). Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160:5729–5734.
   PubMed Web of Science ®Google Scholar
• Blanco, J.C., Contursi, C., Salkowski, C.A., DeWitt, D.L., Ozato, K., Vogel, S.N. (2000). Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J. Exp. Med. 191:2131–2144.
   PubMed Web of Science ®Google Scholar
• Bogdan, C. (2001). Nitric oxide and the immune response. Nat. Immunol. 2:907–916.
   PubMed Web of Science ®Google Scholar
• Braun, D., Longman, R.S., Albert, M.L. (2005). A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106:2375–2381.
   PubMed Web of Science ®Google Scholar
• Brecht, K., Weigert, A., Hu, J., Popp, R., Fisslthaler, B., Korff, T., Fleming, I., Geisslinger, G., and Brune, B. (2011). Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J. 25:2408–2417.
   PubMed Web of Science ®Google Scholar
• Bronte, V. (2009). Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur. J. Immunol. 39:2670–2672.
   PubMed Web of Science ®Google Scholar
• Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N.P., Zanovello, P. (2000). Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96:3838–3846.
   PubMed Web of Science ®Google Scholar
• Bronte, V., Chappell, D.B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P., Restifo, N.P. (1999). Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162: 5728–5737.
   PubMed Web of Science ®Google Scholar
• Bronte, V., Serafini, P., Apolloni, E., Zanovello, P. (2001). Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24:431–446.
   PubMed Web of Science ®Google Scholar
• Bronte, V., Serafini, P., De Santo, C., Marigo, I., Tosello, V., Mazzoni, A., Segal, D.M., Staib, C., Lowel, M., Sutter, G., (2003). IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170:270–278.
   PubMed Web of Science ®Google Scholar
• Bronte, V., Wang, M., Overwijk, W.W., Surman, D.R., Pericle, F., Rosenberg, S.A., Restifo, N.P. (1998). Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161:5313–5320.
   PubMed Web of Science ®Google Scholar
• Bronte, V., Zanovello, P. (2005). Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5:641–654.
   PubMed Web of Science ®Google Scholar
• Byrne, G.I., Lehmann, L.K., Kirschbaum, J.G., Borden, E.C., Lee, C.M., Brown, R.R. (1986). Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J. Interferon Res. 6:389–396.
   PubMedGoogle Scholar
• Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485–490.
   PubMed Web of Science ®Google Scholar
• Cesario, A., Rocca, B., Rutella, S. (2011). The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr. Med. Chem. 18: 2263–2271.
   PubMed Web of Science ®Google Scholar
• Chen, J.H., Wu, C.W., Kao, H.L., Chang, H.M., Li, A.F., Liu, T.Y., Chi, C.W. (2006). Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. Cancer Lett. 239:263–270.
   PubMed Web of Science ®Google Scholar
• Chomarat, P., Banchereau, J., Davoust, J., Palucka, A.K. (2000). IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1:510–514.
   PubMed Web of Science ®Google Scholar
• Chouaib, S., Welte, K., Mertelsmann, R., Dupont, B. (1985). Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J. Immunol. 135:1172–1179.
   PubMed Web of Science ®Google Scholar
• Choudhry, M.A., Ahmed, Z., Sayeed, M.M. (1999). PGE(2)-mediated inhibition of T cell p59(fyn) is independent of cAMP. Am. J. Physiol. 277:C302–309.
   Google Scholar
• Choudhry, M.A., Uddin, S., Sayeed, M.M. (1998). Prostaglandin E2 modulation of p59fyn tyrosine kinase in T lymphocytes during sepsis. J. Immunol. 160:929–935.
   PubMed Web of Science ®Google Scholar
• Condamine, T., Gabrilovich, D.I. (2011). Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32:19–25.
   PubMed Web of Science ®Google Scholar
• Corzo, C.A., Condamine, T., Lu, L., Cotter, M.J., Youn, J.I., Cheng, P., Cho, H.I., Celis, E., Quiceno, D.G., Padhya, T., (2010). HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207:2439–2453.
   PubMed Web of Science ®Google Scholar
• Corzo, C.A., Cotter, M.J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T.V., McCaffrey, J.C., Gabrilovich, D.I. (2009). Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182:5693–5701.
   PubMed Web of Science ®Google Scholar
• Csiki, I., Yanagisawa, K., Haruki, N., Nadaf, S., Morrow, J.D., Johnson, D.H., Carbone, D.P. (2006). Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res. 66:143–150.
   PubMed Web of Science ®Google Scholar
• Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K.L., Daniel, B., Zimmermann, M.C., (2003). Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562–567.
   PubMed Web of Science ®Google Scholar
• Dahiya, Y., Pandey, R.K., Bhatt, K.H., Sodhi, A. (2010). Role of prostaglandin E2 in peptidoglycan mediated iNOS expression in mouse peritoneal macrophages in vitro. FEBS Lett. 584:4227–4232.
   PubMed Web of Science ®Google Scholar
• Delano, M.J., Scumpia, P.O., Weinstein, J.S., Coco, D., Nagaraj, S., Kelly-Scumpia, K.M., O’Malley, K.A., Wynn, J.L., Antonenko, S., Al-Quran, S.Z., (2007). MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204:1463–1474.
   PubMed Web of Science ®Google Scholar
• Donkor, M.K., Lahue, E., Hoke, T.A., Shafer, L.R., Coskun, U., Solheim, J.C., Gulen, D., Bishay, J., Talmadge, J.E. (2009). Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int. Immunopharmacol. 9:937–948.
   PubMed Web of Science ®Google Scholar
• Donnini, S., Finetti, F., Solito, R., Terzuoli, E., Sacchetti, A., Morbidelli, L., Patrignani, P., Ziche, M. (2007). EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J. 21:2418–2430.
   PubMed Web of Science ®Google Scholar
• Duhe, R.J., Evans, G.A., Erwin, R.A., Kirken, R.A., Cox, G.W., Farrar, W.L. (1998). Nitric oxide and thiol redox regulation of Janus kinase activity. Proc. Natl. Acad. Sci. USA 95:126–131.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A.G., Dumitru, C.D., Wang, C.C., Cho, J., Tsichlis, P.N. (2002). Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 21: 4831–4840.
   PubMed Web of Science ®Google Scholar
• Elkabets, M., Ribeiro, V.S., Dinarello, C.A., Ostrand-Rosenberg, S., Di Santo, J.P., Apte, R.N., Vosshenrich, C.A. (2010). IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40:3347–3357.
   PubMed Web of Science ®Google Scholar
• Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J., Kusmartsev, S. (2010). Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE catabolism in myeloid cells. J. Leukocyte Biol. 88:839–848.
   PubMed Web of Science ®Google Scholar
• Eruslanov, E., Daurkin, I., Vieweg, J., Daaka, Y., Kusmartsev, S. (2011). Aberrant PGE metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int. Immunopharmacol. 11:848–855.
   PubMed Web of Science ®Google Scholar
• Eruslanov, E., Kaliberov, S., Daurkin, I., Kaliberova, L., Buchsbaum, D., Vieweg, J., Kusmartsev, S. (2009). Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J. Immunol. 182: 7548–7557.
   PubMed Web of Science ®Google Scholar
• Fallarino, F., Grohmann, U., You, S., McGrath, B.C., Cavener, D.R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M.L., Volpi, C., (2006). The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176:6752–6761.
   PubMed Web of Science ®Google Scholar
• Faour, W.H., He, Y., He, Q.W., de Ladurantaye, M., Quintero, M., Mancini, A., Di Battista, J.A. (2001). Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J. Biol. Chem. 276:31720–31731.
   PubMed Web of Science ®Google Scholar
• Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., Rivoltini, L. (2007). Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25:2546–2553.
   PubMed Web of Science ®Google Scholar
• Fischer, T.A., Palmetshofer, A., Gambaryan, S., Butt, E., Jassoy, C., Walter, U., Sopper, S., Lohmann, S.M. (2001). Activation of cGMP-dependent protein kinase Ibeta inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells. J. Biol. Chem. 276:5967–5974.
   PubMed Web of Science ®Google Scholar
• Fujino, H., Salvi, S., Regan, J.W. (2005). Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol. 68:251–259.
   PubMed Web of Science ®Google Scholar
• Fujino, H., West, K.A., Regan, J.W. (2002). Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J. Biol. Chem. 277:2614–2619.
   PubMed Web of Science ®Google Scholar
• Fujino, H., Xu, W., Regan, J.W. (2003). Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J. Biol. Chem. 278:12151–12156.
   PubMed Web of Science ®Google Scholar
• Fujita, M., Kohanbash, G., Fellows-Mayle, W., Hamilton, R.L., Komohara, Y., Decker, S.A., Ohlfest, J.R., Okada, H. (2011). COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 71:2664–2674.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4:941–952.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., Carbone, D.P. (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, D.I., Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162–174.
   PubMed Web of Science ®Google Scholar
• Gallina, G., Dolcetti, L., Serafini, P., De Santo, C., Marigo, I., Colombo, M.P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., (2006). Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116: 2777–2790.
   PubMed Web of Science ®Google Scholar
• Gerlo, S., Verdood, P., Gellersen, B., Hooghe-Peters, E.L., Kooijman, R. (2004). Mechanism of prostaglandin (PG)E2-induced prolactin expression in human T cells: cooperation of two PGE2 receptor subtypes, E-prostanoid (EP) 3 and EP4, via calcium- and cyclic adenosine 5′-monophosphate-mediated signaling pathways. J. Immunol. 173:5952–5962.
   PubMed Web of Science ®Google Scholar
• Goodwin, J.S., Ceuppens, J. (1983). Regulation of the immune response by prostaglandins. J. Clin. Immunol. 3:295–315.
   PubMed Web of Science ®Google Scholar
• Goto, T., Herberman, R.B., Maluish, A., Strong, D.M. (1983). Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J. Immunol. 130: 1350–1355.
   PubMed Web of Science ®Google Scholar
• Greifenberg, V., Ribechini, E., Rossner, S., Lutz, M.B. (2009). Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 39:2865–2876.
   PubMed Web of Science ®Google Scholar
• Haas, A.R., Sun, J., Vachani, A., Wallace, A.F., Silverberg, M., Kapoor, V., Albelda, S.M. (2006). Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin. Cancer Res. 12:214–222.
   Google Scholar
• Hahn, T., Alvarez, I., Kobie, J.J., Ramanathapuram, L., Dial, S., Fulton, A., Besselsen, D., Walker, E., Akporiaye, E.T. (2006). Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Inter. J. Cancer 118:2220–2231.
   PubMed Web of Science ®Google Scholar
• Harris, A.L. (2002). Hypoxia–a key regulatory factor in tumour growth. Nature Rev. Cancer 2:38–47.
   PubMed Web of Science ®Google Scholar
• Hendricks, A., Leibold, W., Kaever, V., Schuberth, H.J. (2000). Prostaglandin E2 is variably induced by bacterial superantigens in bovine mononuclear cells and has a regulatory role for the T cell proliferative response. Immunobiology 201:493–505.
   PubMed Web of Science ®Google Scholar
• Hoechst, B., Ormandy, L.A., Ballmaier, M., Lehner, F., Kruger, C., Manns, M.P., Greten, T.F., Korangy, F. (2008). A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135:234–243.
   PubMed Web of Science ®Google Scholar
• Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M.P., Greten, T.F., Korangy, F. (2009). Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50:799–807.
   PubMed Web of Science ®Google Scholar
• Holt, D., Ma, X., Kundu, N., Fulton, A. (2011). Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol. Immunother. 60:1577–1586.
   PubMed Web of Science ®Google Scholar
• Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., Narumiya, S., Ichikawa, A. (1993). Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem. 268:7759–7762.
   PubMed Web of Science ®Google Scholar
• Huang, B., Pan, P.Y., Li, Q., Sato, A.I., Levy, D.E., Bromberg, J., Divino, C.M., Chen, S.H. (2006). Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123–1131.
   PubMed Web of Science ®Google Scholar
• Hwu, P., Du, M.X., Lapointe, R., Do, M., Taylor, M.W., Young, H.A. (2000). Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164:3596–3599.
   PubMed Web of Science ®Google Scholar
• Jung, Y.J., Isaacs, J.S., Lee, S., Trepel, J., Neckers, L. (2003). IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17:2115–2117.
   PubMed Web of Science ®Google Scholar
• Kalinski, P. (2012). Regulation of immune responses by prostaglandin E2. J. Immunol. 188:21–28.
   PubMed Web of Science ®Google Scholar
• Kalinski, P., Hilkens, C.M., Snijders, A., Snijdewint, F.G., Kapsenberg, M.L. (1997). IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 159:28–35.
   PubMed Web of Science ®Google Scholar
• Kalinski, P., Hilkens, C.M., Wierenga, E.A., Kapsenberg, M.L. (1999). T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20:561–567.
   PubMedGoogle Scholar
• Kalinski, P., Schuitemaker, J.H., Hilkens, C.M., Kapsenberg, M.L. (1998). Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161:2804–2809.
   PubMed Web of Science ®Google Scholar
• Kanayama, S., Yamada, Y., Kawaguchi, R., Tsuji, Y., Haruta, S., Kobayashi, H. (2008). Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. Oncol. Rep. 19:117–122.
   PubMed Web of Science ®Google Scholar
• Katz, J.B., Muller, A.J., Prendergast, G.C. (2008). Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222:206–221.
   PubMed Web of Science ®Google Scholar
• Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mule, J., Kerr, W.G., (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11:1314–1321.
   PubMed Web of Science ®Google Scholar
• Kusmartsev, S., Gabrilovich, D.I. (2003). Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukocyte Biol. 74:186–196.
   PubMed Web of Science ®Google Scholar
• Kusmartsev, S., Gabrilovich, D.I. (2005). STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174:4880–4891.
   PubMed Web of Science ®Google Scholar
• Kusmartsev, S., Nagaraj, S., Gabrilovich, D.I. (2005). Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175:4583–4592.
   PubMed Web of Science ®Google Scholar
• Lee, S.Y., Choi, H.K., Lee, K.J., Jung, J.Y., Hur, G.Y., Jung, K.H., Kim, J.H., Shin, C., Shim, J.J. In, K.H., (2009). The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother. 32:22–28.
   PubMed Web of Science ®Google Scholar
• Li, H., Han, Y., Guo, Q., Zhang, M., Cao, X. (2009). Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182:240–249.
   PubMed Web of Science ®Google Scholar
• Linnemeyer, P.A., and Pollack, S.B. (1993). Prostaglandin E2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells. J. Immunol. 150:3747–3754.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Zeng, B., Zhang, Z., Zhang, Y., Yang, R. (2008). B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin. Immunol. 129:471–481.
   PubMed Web of Science ®Google Scholar
• Mannick, J.B., Hausladen, A., Liu, L., Hess, D.T., Zeng, M., Miao, Q.X., Kane, L.S., Gow, A.J., Stamler, J.S. (1999). Fas-induced caspase denitrosylation. Science 284:651–654.
   PubMed Web of Science ®Google Scholar
• Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J.H., Apolloni, E., Serafini, P., Zanovello, P., Segal, D.M. (2002). Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168:689–695.
   PubMed Web of Science ®Google Scholar
• Mellor, A.L., Munn, D.H. (2004). IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4:762–774.
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux, C., Montmain, G., Dieu, M.C., Bain, C., Favrot, M.C., Caux, C., Blay, J.Y. (1998). Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92:4778–4791.
   PubMed Web of Science ®Google Scholar
• Moore, A.E., Greenhough, A., Roberts, H.R., Hicks, D.J., Patsos, H.A., Williams, A.C., Paraskeva, C. (2009). HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis 30:1796–1804.
   PubMed Web of Science ®Google Scholar
• Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., Van Ginderachter, J.A. (2008). Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233–4244.
   PubMed Web of Science ®Google Scholar
• Mukherjee, P., Basu, G.D., Tinder, T.L., Subramani, D.B., Bradley, J.M., Arefayene, M., Skaar, T., De Petris, G. (2009). Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol. 182:216–224.
   PubMed Web of Science ®Google Scholar
• Muller, A.J., Scherle, P.A. (2006). Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6:613–625.
   PubMed Web of Science ®Google Scholar
• Mundy-Bosse, B.L., Young, G.S., Bauer, T., Binkley, E., Bloomston, M., Bill, M.A., Bekaii-Saab, T., Carson, W.E., 3rd, Lesinski, G.B. (2011). Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011; 60(9):1269–1279.
   PubMed Web of Science ®Google Scholar
• Munn, D.H., Mellor, A.L. (2007). Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117:1147–1154.
   PubMed Web of Science ®Google Scholar
• Munn, D.H., Shafizadeh, E., Attwood, J.T., Bondarev, I., Pashine, A., Mellor, A.L. (1999). Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189:1363–1372.
   PubMed Web of Science ®Google Scholar
• Murdoch, C., Muthana, M., Coffelt, S.B., Lewis, C.E. (2008). The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8:618–631.
   PubMed Web of Science ®Google Scholar
• Naito, Y., Endo, H., Arai, K., Coffman, R.L., Arai, N. (1996). Signal transduction in Th clones: target of differential modulation by PGE2 may reside downstream of the PKC-dependent pathway. Cytokine 8:346–356.
   PubMed Web of Science ®Google Scholar
• Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., Gabrilovich, D. (2004). Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172:464–474.
   PubMed Web of Science ®Google Scholar
• Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S.M., Gabrilovich, D.I. (2005). Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65:9525–9535.
   PubMed Web of Science ®Google Scholar
• Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R.P., Kalinski, P. (2011a). Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118:5498–5505.
   PubMed Web of Science ®Google Scholar
• Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R.P., Kalinski, P. (2011b). PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71:7463–7470.
   PubMed Web of Science ®Google Scholar
• Ochoa, A.C., Zea, A.H., Hernandez, C., Rodriguez, P.C. (2007). Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13:721s–726s.
   PubMed Web of Science ®Google Scholar
• Orabona, C., Pallotta, M.T., Volpi, C., Fallarino, F., Vacca, C., Bianchi, R., Belladonna, M.L., Fioretti, M.C., Grohmann, U., Puccetti, P. (2008). SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci. USA 105:20828–20833.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg, S. (2010). Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59:1593–1600.
   PubMed Web of Science ®Google Scholar
• Ozaki, Y., Edelstein, M.P., Duch, D.S. (1988). Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc. Natl. Acad. Sci. USA 85:1242–1246.
   PubMed Web of Science ®Google Scholar
• Pan, P.Y., Ma, G., Weber, K.J., Ozao-Choy, J., Wang, G., Yin, B., Divino, C.M., Chen, S.H. (2010). Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 70:99–108.
   PubMed Web of Science ®Google Scholar
• Pan, P.Y., Wang, G.X., Yin, B., Ozao, J., Ku, T., Divino, C.M., Chen, S.H. (2008). Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111:219–228.
   PubMed Web of Science ®Google Scholar
• Parhar, R.S., Lala, P.K. (1988). Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J. Leukocyte Biol. 44:474–484.
   PubMed Web of Science ®Google Scholar
• Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., Bronte, V. (2010). Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22:238–244.
   PubMed Web of Science ®Google Scholar
• Prendergast, G.C. (2008). Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27:3889–3900.
   PubMed Web of Science ®Google Scholar
• Prendergast, G.C., Metz, R., Muller, A.J. (2010). Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Amer. J. Pathol. 176:2082–2087.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E.C., Garcia, J., Vogelbaum, M.A., Finke, J. (2011). Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro. Oncol. 13:591–599.
   PubMed Web of Science ®Google Scholar
• Regan, J.W., Bailey, T.J., Pepperl, D.J., Pierce, K.L., Bogardus, A.M., Donello, J.E., Fairbairn, C.E., Kedzie, K.M., Woodward, D.F., Gil, D.W. (1994). Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol. 46:213–220.
   PubMed Web of Science ®Google Scholar
• Rodriguez, P.C., Ernstoff, M.S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R., Ochoa, A.C. (2009). Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69:1553–1560.
   PubMed Web of Science ®Google Scholar
• Rodriguez, P.C., Hernandez, C.P., Quiceno, D., Dubinett, S.M., Zabaleta, J., Ochoa, J.B., Gilbert, J., Ochoa, A.C. (2005). Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202:931–939.
   PubMed Web of Science ®Google Scholar
• Rodriguez, P.C., Ochoa, A.C. (2008). Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222:180–191.
   PubMed Web of Science ®Google Scholar
• Rodriguez, P.C., Quiceno, D.G., Zabaleta, J., Ortiz, B., Zea, A.H., Piazuelo, M.B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E.M., (2004). Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64:5839–5849.
   PubMed Web of Science ®Google Scholar
• Rodriguez, P.C., Zea, A.H., DeSalvo, J., Culotta, K.S., Zabaleta, J., Quiceno, D.G., Ochoa, J.B., Ochoa, A.C. (2003). L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171:1232–1239.
   PubMed Web of Science ®Google Scholar
• Rutella, S., Bonanno, G., Procoli, A., Mariotti, A., de Ritis, D.G., Curti, A., Danese, S., Pessina, G., Pandolfi, S., Natoni, F., (2006). Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 108:218–227.
   PubMed Web of Science ®Google Scholar
• Scarpino, S., Duranti, E., Stoppacciaro, A., Pilozzi, E., Natoli, G., Sciacchitano, S., Luciani, E., Ruco, L. (2009). COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. J. Pathol. 218:487–494.
   PubMed Web of Science ®Google Scholar
• Schmedtje, J.F., Jr., Ji, Y.S., Liu, W.L., DuBois, R.N., Runge, M.S. (1997). Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 272:601–608.
   PubMed Web of Science ®Google Scholar
• Schmielau, J., Finn, O.J. (2001). Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 61:4756–4760.
   PubMed Web of Science ®Google Scholar
• Schwacha, M.G., Ayala, A., Cioffi, W.G., Bland, K.I., Chaudry, I.H. (1999). Role of protein kinase C in cyclic AMP-mediated suppression of T-lymphocyte activation following burn injury. Biochim. Biophys. Acta 1455:45–53.
   PubMed Web of Science ®Google Scholar
• Semenza, G.L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721–732.
   PubMed Web of Science ®Google Scholar
• Serafini, P. (2010). Editorial: PGE2-producing MDSC: a role in tumor progression? J. Leukocyte Biol. 88:827–829.
   PubMed Web of Science ®Google Scholar
• Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., Borrello, I. (2006). Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203:2691–2702.
   PubMed Web of Science ®Google Scholar
• Serafini, P., Mgebroff, S., Noonan, K., Borrello, I. (2008). Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68:5439–5449.
   PubMed Web of Science ®Google Scholar
• Sharma, M.D., Baban, B., Chandler, P., Hou, D.Y., Singh, N., Yagita, H., Azuma, M., Blazar, B.R., Mellor, A.L., Munn, D.H. (2007). Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117:2570–2582.
   PubMed Web of Science ®Google Scholar
• Sharma, S., Yang, S.C., Zhu, L., Reckamp, K., Gardner, B., Baratelli, F., Huang, M., Batra, R.K., Dubinett, S.M. (2005a). Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 65:5211–5220.
   PubMed Web of Science ®Google Scholar
• Sharma, S., Zhu, L., Yang, S.C., Zhang, L., Lin, J., Hillinger, S., Gardner, B., Reckamp, K., Strieter, R.M., Huang, M., (2005b). Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J. Immunol. 175:813–819.
   PubMed Web of Science ®Google Scholar
• Siegfried, J.M., Gubish, C.T., Rothstein, M.E., Queiroz de Oliveira, P.E., Stabile, L.P. (2007). Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Mol. Pharmacol. 72:769–779.
   PubMed Web of Science ®Google Scholar
• Sinha, P., Clements, V.K., Bunt, S.K., Albelda, S.M., Ostrand-Rosenberg, S. (2007a). Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:977–983.
   PubMed Web of Science ®Google Scholar
• Sinha, P., Clements, V.K., Fulton, A.M., Ostrand-Rosenberg, S. (2007b). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67: 4507–4513.
   PubMed Web of Science ®Google Scholar
• Sinha, P., Clements, V.K., Ostrand-Rosenberg, S. (2005). Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174:636–645.
   PubMed Web of Science ®Google Scholar
• Specht, C., Bexten, S., Kolsch, E., Pauels, H.G. (2001). Prostaglandins, but not tumor-derived IL-10, shut down concomitant tumor-specific CTL responses during murine plasmacytoma progression. Inter. J. Cancer 91:705–712.
   PubMed Web of Science ®Google Scholar
• Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P.W., Portanova, J., (2000). Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164:361–370.
   PubMed Web of Science ®Google Scholar
• Su, Y., Jackson, E.K., Gorelik, E. (2011). Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol. Immunother. 60:111–122.
   PubMed Web of Science ®Google Scholar
• Subbaramaiah, K., Dannenberg, A.J. (2003). Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24:96–102.
   PubMed Web of Science ®Google Scholar
• Tai, H.H., Ensor, C.M., Tong, M., Zhou, H., Yan, F. (2002). Prostaglandin catabolizing enzymes. Prostaglandins Lipid Mediat. 68–69:483–493.
   PubMed Web of Science ®Google Scholar
• Talmadge, J.E., Hood, K.C., Zobel, L.C., Shafer, L.R., Coles, M., Toth, B. (2007). Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int. Immunopharmacol. 7:140–151.
   PubMed Web of Science ®Google Scholar
• Timoshenko, A.V., Lala, P.K., Chakraborty, C. (2004). PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. Inter. J. Cancer 108:384–389.
   PubMed Web of Science ®Google Scholar
• Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., Van den Eynde, B.J. (2003). Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:1269–1274.
   PubMed Web of Science ®Google Scholar
• Van Ginderachter, J.A., Meerschaut, S., Liu, Y., Brys, L., De Groeve, K., Hassanzadeh Ghassabeh, G., Raes, G., De Baetselier, P. (2006). Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 108:525–535.
   PubMed Web of Science ®Google Scholar
• Vang, T., Abrahamsen, H., Myklebust, S., Horejsi, V., Tasken, K. (2003). Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J. Biol. Chem. 278:17597–17600.
   PubMedGoogle Scholar
• Veltman, J.D., Lambers, M.E., van Nimwegen, M., Hendriks, R.W., Hoogsteden, H.C., Aerts, J.G., Hegmans, J.P. (2010). COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 10:464.
   PubMed Web of Science ®Google Scholar
• von Bergwelt-Baildon, M.S., Popov, A., Saric, T., Chemnitz, J., Classen, S., Stoffel, M.S., Fiore, F., Roth, U., Beyer, M., Debey, S., (2006). CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108:228–237.
   PubMed Web of Science ®Google Scholar
• Vuk-Pavlovic, S., Bulur, P.A., Lin, Y., Qin, R., Szumlanski, C.L., Zhao, X., Dietz, A.B. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 70:443–455.
   PubMedGoogle Scholar
• Wu, C.Y., Wang, K., McDyer, J.F., Seder, R.A. (1998). Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 161:2723–2730.
   PubMed Web of Science ®Google Scholar
• Xia, Y., Roman, L.J., Masters, B.S., Zweier, J.L. (1998). Inducible nitric-oxide synthase generates superoxide from the reductase domain. J. Biol. Chem. 273:22635–22639.
   PubMed Web of Science ®Google Scholar
• Xia, Y., Zweier, J.L. (1997). Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. USA 94:6954–6958.
   PubMed Web of Science ®Google Scholar
• Xu, H., Oriss, T.B., Fei, M., Henry, A.C., Melgert, B.N., Chen, L., Mellor, A.L., Munn, D.H., Irvin, C.G., Ray, P., (2008a). Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl. Acad. Sci. USA 105:6690–6695.
   PubMed Web of Science ®Google Scholar
• Xu, H., Zhang, G.X., Ciric, B., Rostami, A. (2008b). IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol. Lett. 121:1–6.
   PubMed Web of Science ®Google Scholar
• Yakar, I., Melamed, R., Shakhar, G., Shakhar, K., Rosenne, E., Abudarham, N., Page, G.G., and Ben-Eliyahu, S. (2003). Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann. Surg. Oncol. 10:469–479.
   PubMed Web of Science ®Google Scholar
• Yang, L., DeBusk, L.M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L.M., Carbone, D.P., Lin, P.C. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421.
   PubMed Web of Science ®Google Scholar
• Yang, R., Cai, Z., Zhang, Y., Yutzy, W.H.t., Roby, K.F., Roden, R.B. (2006). CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 66:6807–6815.
   PubMed Web of Science ®Google Scholar
• Youn, J.I., Nagaraj, S., Collazo, M., Gabrilovich, D.I. (2008). Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:5791–5802.
   PubMed Web of Science ®Google Scholar
• Young, M.R., Wright, M.A. (1992). Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis. Cancer Res. 52:6335–6340.
   PubMed Web of Science ®Google Scholar